Cargando…

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure

BACKGROUND AND OBJECTIVES: Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have a cardiovascular benefit in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Chang-Myung, Cho, Sungsoo, Jang, Ji-Yong, Kim, Hyeongseok, Chun, Sukyung, Choi, Minkyung, Park, Sangkyu, Ko, Young-Guk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875592/ https://www.ncbi.nlm.nih.gov/pubmed/31456369 http://dx.doi.org/10.4070/kcj.2019.0180

Ejemplares similares

SGLT-2 inhibitors as cardioprotective agents in COVID-19
por: Gupta, Kashish, et al.
Publicado: (2020)

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
por: Tentolouris, Anastasios, et al.
Publicado: (2019)

Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors
por: Fender, Anke C., et al.
Publicado: (2023)

Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
por: Aali, Ehsan, et al.
Publicado: (2021)

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na(+)?
por: Trum, Maximilian, et al.
Publicado: (2021)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
por: Al Thani, Najlaa A., et al.
Publicado: (2023)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Cardioprotection in right heart failure
por: Boengler, Kerstin, et al.
Publicado: (2020)

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
por: Jiang, Kai, et al.
Publicado: (2021)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Inhibition of Serotonin Synthesis Induces Negative Hepatic Lipid Balance
por: Namkung, Jun, et al.
Publicado: (2018)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Quercetin-induced cardioprotection against doxorubicin cytotoxicity
por: Chen, Jing-Yi, et al.
Publicado: (2013)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
por: Pabel, Steffen, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Mitochondrial Quality Control in the Heart: New Drug Targets for Cardiovascular Disease
por: Oh, Chang-Myung, et al.
Publicado: (2020)

Cardioprotective Effects of Ghrelin in Heart Failure: From Gut to Heart
por: Khatib, Mahalaqua Nazli, et al.
Publicado: (2014)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2022)

Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure
por: Mastorci, Francesca, et al.
Publicado: (2020)

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
por: Williams, David M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5en3lsjo265td4o46sl3cnfli0